uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Senstend
Withdrawn
Human
Details
EMA number
EMEA/H/C/005298
ATC code
N01BB20
Authorisation
14 November 2019
Revision
-
EMA page
Therapeutic indication
Senstend is indicated for the treatment of primary premature ejaculation in adult men.
MeSH:
Premature Ejaculation
Group:
Anesthetics
Active substances
lidocaine
prilocaine
Marketing Authorisation Holder
Plethora Pharma Solutions Limited
MAH
Timeline
Filter by authority:
EMA
Senstend authorised
14 Nov 2019
authorised
regulatory
Senstend | uMedical